PDE4B-IN-6

• Description:

  PDE4B-IN-6 (compound 4i) is a potent and selective PDE4B inhibitor with an IC50 of 7.42 nM. PDE4B-IN-6 shows ~195- and ~169-fold selectivity for PDE4B over PDE4A (IC50 = 1540 nM) and PDE4C (IC50 = 1260 nM), respectively. PDE4B-IN-6 increases cAMP level and suppresses TNF-α expression. PDE4B-IN-6 shows favorable antioxidant profiles and low cytotoxicity. PDE4B-IN-6 can be used for chronic obstructive pulmonary disease (COPD) research[1].

• UNSPSC:

  12352005

• Target:

  Phosphodiesterase (PDE) ; TNF Receptor

• Related Pathways:

  Apoptosis; Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Smiles:

  O=C(NNC(C1=CC=C(OC(F)F)C(OCC2CC2)=C1)=O)C3=CC(OC)=C(OC)C(OC)=C3

• Molecular Formula:

  C22H24F2N2O7

• Molecular Weight:

  466.43

• References & Citations:

  [1]Moussa AM, et al. Design and development of potent roflumilast analogues targeting PDE-4B: selectivity and pharmacokinetic insights. Bioorg Chem. 2025 Dec;167:109201.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  PDE4